ValuEngine lowered shares of FibroGen (NASDAQ:FGEN) from a hold rating to a sell rating in a research note issued to investors on Friday.
A number of other brokerages have also commented on FGEN. Jefferies Group reiterated a buy rating and issued a $75.00 target price on shares of FibroGen in a research report on Tuesday, September 12th. Leerink Swann reiterated an outperform rating and issued a $82.00 target price (up previously from $52.00) on shares of FibroGen in a research report on Tuesday, August 8th. Stifel Nicolaus upped their target price on FibroGen from $38.00 to $80.00 and gave the company a buy rating in a research report on Tuesday, August 8th. William Blair reiterated an outperform rating on shares of FibroGen in a research report on Wednesday, August 9th. Finally, Mizuho started coverage on FibroGen in a research report on Wednesday, October 4th. They issued a neutral rating and a $61.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $65.67.
Shares of FibroGen (NASDAQ:FGEN) traded down $0.35 during midday trading on Friday, reaching $47.15. The company had a trading volume of 481,100 shares, compared to its average volume of 619,192. FibroGen has a 52-week low of $19.25 and a 52-week high of $60.15. The company has a debt-to-equity ratio of 0.16, a quick ratio of 10.83 and a current ratio of 10.83.
A number of institutional investors have recently added to or reduced their stakes in FGEN. Quantbot Technologies LP purchased a new position in shares of FibroGen during the 2nd quarter valued at approximately $128,000. Oppenheimer Asset Management Inc. lifted its position in shares of FibroGen by 112.6% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 4,410 shares of the biopharmaceutical company’s stock valued at $237,000 after buying an additional 2,336 shares in the last quarter. Ameritas Investment Partners Inc. lifted its position in shares of FibroGen by 15.4% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock valued at $169,000 after buying an additional 696 shares in the last quarter. BBR Partners LLC purchased a new position in shares of FibroGen during the 3rd quarter valued at approximately $299,000. Finally, Teacher Retirement System of Texas purchased a new position in shares of FibroGen during the 3rd quarter valued at approximately $299,000. Institutional investors and hedge funds own 57.42% of the company’s stock.
FibroGen Company Profile
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
To view ValuEngine’s full report, visit ValuEngine’s official website.
What are top analysts saying about FibroGen Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for FibroGen Inc and related companies.